Impacts of COVID-19 on Medtech, Biotech & Clinical Trials
postponed and will be re-scheduled for in-person - date to be advised
has had an undeniable impact on all business sectors, and highlighted
the importance of continued advancements in Medtech, Biotech and
Clinical Trials. The patent box announced in the recent Federal Budget
indicates positive support for these industries, though what has been
the impact of the pandemic on these sectors? How have the industries
responded? What’s next as the industries are normalised
Join our panel of experts as we discuss the implications of COVID-19 on all things Medtech, Biotech and Clinical Trials
~ The impact of COVID-19 on the conduct of Australian Clinical Trials, Medtech development, and Biotech development.
~ Government responses and incentives for the clinical trial, Medtech and Biotech industries
~ Moving forward: Industry expectations and patent box (as announced in the recent Federal Budget)
This is an interactive session and there will also be the opportunity for Q&A.
Proudly supported by:
Online registration not available.